Literature DB >> 15605984

Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.

Masahiro Mizoguchi1, Catherine L Nutt, Gayatry Mohapatra, David N Louis.   

Abstract

Genetic alterations of PI3K (phosphoinositide 3-kinase) subunits have been documented in a number of tumor types, with increased PI3K activity linked to gene amplification and mutation of catalytic subunits, as well as mutations of regulatory subunits. Among high grade gliomas, activation of the PI3K-AKT signaling pathway through loss of PTEN function is common. We therefore investigated whether genetic alteration of class IA PI3Ks might provide a mechanism for deregulation of this pathway in glioblastomas. We studied a series of glioblastomas with FISH to assess copy number of catalytic subunits (PIK3CA and PIK3CD) and with PCR-SSCP to screen for somatic mutations of conserved regions of both catalytic and regulatory subunits. FISH revealed frequent balanced copy number increases of both PIK3CA and PIK3CD, and one case showed an extra copy limited to PIK3CA. One glioblastoma exhibited a 9-bp deletion that encompassed the exon-intron junction of exon 12 of PIK3R1, documenting for the first time a mutation within a PI3K regulatory subunit in human glioblastoma. This deletion would be predicted to yield a truncated protein that lacks the inhibitory domain, resulting in increased PI3K activity. Furthermore, the case with selected PIK3CA copy number gain and the case with a truncating PIK3R1 mutation both featured AKT activation without PTEN mutation. These results suggest that genetic alterations of class IA PI3K subunit genes can occasionally play a role in human glioblastoma by activating the PI3K-AKT signaling pathway independently of PTEN mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605984     DOI: 10.1111/j.1750-3639.2004.tb00080.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  44 in total

1.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

Review 2.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 3.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

4.  Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis.

Authors:  Claire L Simpson; Cheryl D Cropp; Tiina Wahlfors; Asha George; Marypat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Teuvo Tammela; Johanna Schleutker; Joan E Bailey-Wilson
Journal:  Eur J Hum Genet       Date:  2012-09-05       Impact factor: 4.246

5.  Tocotrienols fight cancer by targeting multiple cell signaling pathways.

Authors:  Ramaswamy Kannappan; Subash C Gupta; Ji Hye Kim; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-09       Impact factor: 5.523

Review 6.  Targeting the PI3K pathway for cancer therapy.

Authors:  Navid Sadeghi; David E Gerber
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

Review 7.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

8.  Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation.

Authors:  M Dean Chamberlain; Tim Chan; Jennifer C Oberg; Andrea D Hawrysh; Kristy M James; Anurag Saxena; Jim Xiang; Deborah H Anderson
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

Review 9.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.